QuantRx Biomedical Corporation (QTXB)
USD 0.0
(400.0%)
USD 0.0
(400.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | - USD | -100.0% |
| 2021 | 43.38 Thousand USD | -28.44% |
| 2020 | 60.62 Thousand USD | -69.95% |
| 2019 | 201.73 Thousand USD | -14.47% |
| 2018 | 235.87 Thousand USD | 42.81% |
| 2017 | 165.17 Thousand USD | 18.97% |
| 2016 | 138.83 Thousand USD | -61.31% |
| 2015 | 358.86 Thousand USD | -22.48% |
| 2014 | 462.93 Thousand USD | 21.03% |
| 2013 | 382.48 Thousand USD | -24.88% |
| 2012 | 509.17 Thousand USD | -37.56% |
| 2011 | 815.44 Thousand USD | -76.69% |
| 2010 | 3.49 Million USD | -29.01% |
| 2009 | 4.92 Million USD | -21.32% |
| 2008 | 6.26 Million USD | -6.97% |
| 2007 | 6.73 Million USD | 116.94% |
| 2006 | 3.1 Million USD | 270.33% |
| 2005 | 837.84 Thousand USD | 1409.2% |
| 2004 | 55.51 Thousand USD | -41.25% |
| 2003 | 94.49 Thousand USD | -20.77% |
| 2002 | 119.27 Thousand USD | -84.31% |
| 2001 | 760 Thousand USD | -55.03% |
| 2000 | 1.69 Million USD | -26.52% |
| 1999 | 2.3 Million USD | -49.23% |
| 1998 | 4.53 Million USD | 14.68% |
| 1997 | 3.95 Million USD | -11.63% |
| 1996 | 4.47 Million USD | 8.5% |
| 1995 | 4.12 Million USD | 292.38% |
| 1994 | 1.05 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2022 FY | - USD | -100.0% |
| 2022 Q1 | 3606.00 USD | -45.06% |
| 2022 Q2 | 26.9 Thousand USD | 645.98% |
| 2022 Q4 | - USD | -100.0% |
| 2022 Q3 | 7250.00 USD | -73.05% |
| 2021 Q3 | 8542.00 USD | -63.23% |
| 2021 Q2 | 23.23 Thousand USD | 360.29% |
| 2021 FY | 43.38 Thousand USD | -28.44% |
| 2021 Q1 | 5047.00 USD | -44.49% |
| 2021 Q4 | 6563.00 USD | -23.17% |
| 2020 Q3 | 10.69 Thousand USD | -57.97% |
| 2020 Q4 | 9092.00 USD | -14.96% |
| 2020 Q2 | 25.44 Thousand USD | 65.19% |
| 2020 Q1 | 15.4 Thousand USD | -57.25% |
| 2020 FY | 60.62 Thousand USD | -69.95% |
| 2019 FY | 201.73 Thousand USD | -14.47% |
| 2019 Q1 | 59 Thousand USD | -26.56% |
| 2019 Q2 | 61.83 Thousand USD | 4.8% |
| 2019 Q3 | 44.87 Thousand USD | -27.42% |
| 2019 Q4 | 36.02 Thousand USD | -19.74% |
| 2018 Q3 | 25.58 Thousand USD | -69.41% |
| 2018 Q4 | 80.34 Thousand USD | 214.03% |
| 2018 Q2 | 83.64 Thousand USD | 80.64% |
| 2018 Q1 | 46.3 Thousand USD | -23.96% |
| 2018 FY | 235.87 Thousand USD | 42.81% |
| 2017 Q3 | 32.74 Thousand USD | -6.5% |
| 2017 FY | 165.17 Thousand USD | 18.97% |
| 2017 Q1 | 36.5 Thousand USD | 14.77% |
| 2017 Q2 | 35.02 Thousand USD | -4.06% |
| 2017 Q4 | 60.89 Thousand USD | 85.94% |
| 2016 FY | 138.83 Thousand USD | -61.31% |
| 2016 Q1 | 26.64 Thousand USD | -62.73% |
| 2016 Q4 | 31.81 Thousand USD | 18.22% |
| 2016 Q3 | 26.9 Thousand USD | -49.68% |
| 2016 Q2 | 53.47 Thousand USD | 100.7% |
| 2015 Q2 | 38.76 Thousand USD | -77.64% |
| 2015 FY | 358.86 Thousand USD | -22.48% |
| 2015 Q4 | 71.48 Thousand USD | -4.99% |
| 2015 Q1 | 173.37 Thousand USD | 33.04% |
| 2015 Q3 | 75.24 Thousand USD | 94.13% |
| 2014 Q3 | 83.67 Thousand USD | -46.64% |
| 2014 Q4 | 130.31 Thousand USD | 55.74% |
| 2014 Q1 | 92.15 Thousand USD | -52.43% |
| 2014 Q2 | 156.79 Thousand USD | 70.15% |
| 2014 FY | 462.93 Thousand USD | 21.03% |
| 2013 Q2 | 90.92 Thousand USD | 87.49% |
| 2013 Q3 | 49.34 Thousand USD | -45.73% |
| 2013 Q4 | 193.72 Thousand USD | 292.62% |
| 2013 Q1 | 48.49 Thousand USD | 224.97% |
| 2013 FY | 382.48 Thousand USD | -24.88% |
| 2012 Q4 | 14.92 Thousand USD | -90.87% |
| 2012 Q2 | 186.15 Thousand USD | 28.63% |
| 2012 Q3 | 163.37 Thousand USD | -12.24% |
| 2012 Q1 | 144.72 Thousand USD | -44.54% |
| 2012 FY | 509.17 Thousand USD | -37.56% |
| 2011 Q4 | 260.94 Thousand USD | 63.83% |
| 2011 FY | 815.44 Thousand USD | -76.69% |
| 2011 Q3 | 159.27 Thousand USD | -40.57% |
| 2011 Q2 | 268.01 Thousand USD | 110.68% |
| 2011 Q1 | 127.21 Thousand USD | -67.09% |
| 2010 FY | 3.49 Million USD | -29.01% |
| 2010 Q3 | 924.84 Thousand USD | -8.24% |
| 2010 Q1 | 1.17 Million USD | -28.55% |
| 2010 Q2 | 1 Million USD | -14.49% |
| 2010 Q4 | 386.6 Thousand USD | -58.2% |
| 2009 Q3 | 1.99 Million USD | 286.39% |
| 2009 Q2 | 516.52 Thousand USD | -53.94% |
| 2009 Q4 | 1.64 Million USD | -17.34% |
| 2009 Q1 | 1.12 Million USD | 2.25% |
| 2009 FY | 4.92 Million USD | -21.32% |
| 2008 Q2 | 1.9 Million USD | 18.25% |
| 2008 Q1 | 1.6 Million USD | -51.47% |
| 2008 FY | 6.26 Million USD | -6.97% |
| 2008 Q4 | 1.09 Million USD | -33.8% |
| 2008 Q3 | 1.65 Million USD | -12.87% |
| 2007 Q3 | 1.14 Million USD | -19.98% |
| 2007 FY | 6.73 Million USD | 116.94% |
| 2007 Q2 | 1.42 Million USD | 69.47% |
| 2007 Q4 | 3.31 Million USD | 189.54% |
| 2007 Q1 | 843.74 Thousand USD | -46.01% |
| 2006 Q4 | 1.56 Million USD | 191.82% |
| 2006 Q2 | 658.98 Thousand USD | 90.73% |
| 2006 Q1 | 345.5 Thousand USD | 25.48% |
| 2006 FY | 3.1 Million USD | 270.33% |
| 2006 Q3 | 535.53 Thousand USD | -18.73% |
| 2005 Q3 | 388.93 Thousand USD | 208.71% |
| 2005 Q1 | 47.58 Thousand USD | 321.48% |
| 2005 Q4 | 275.33 Thousand USD | -29.21% |
| 2005 FY | 837.84 Thousand USD | 1409.2% |
| 2005 Q2 | 125.98 Thousand USD | 164.76% |
| 2004 Q1 | 39.31 Thousand USD | 0.0% |
| 2004 Q2 | 20.14 Thousand USD | -48.76% |
| 2004 Q3 | 15.12 Thousand USD | -24.91% |
| 2004 Q4 | -21.48 Thousand USD | -242.03% |
| 2004 FY | 55.51 Thousand USD | -41.25% |
| 2003 FY | 94.49 Thousand USD | -20.77% |
| 2002 FY | 119.27 Thousand USD | -84.31% |
| 2002 Q1 | 30 Thousand USD | -50.0% |
| 2001 Q4 | 60 Thousand USD | -66.67% |
| 2001 FY | 760 Thousand USD | -55.03% |
| 2001 Q3 | 180 Thousand USD | -25.0% |
| 2001 Q2 | 240 Thousand USD | -14.29% |
| 2001 Q1 | 280 Thousand USD | -30.0% |
| 2000 Q4 | 400 Thousand USD | -9.09% |
| 2000 FY | 1.69 Million USD | -26.52% |
| 2000 Q1 | 420 Thousand USD | -14.29% |
| 2000 Q2 | 430 Thousand USD | 2.38% |
| 2000 Q3 | 440 Thousand USD | 2.33% |
| 1999 Q4 | 490 Thousand USD | -10.91% |
| 1999 Q3 | 550 Thousand USD | -8.33% |
| 1999 Q1 | 639.99 Thousand USD | -48.8% |
| 1999 FY | 2.3 Million USD | -49.23% |
| 1999 Q2 | 600 Thousand USD | -6.25% |
| 1998 Q2 | 950 Thousand USD | -20.17% |
| 1998 Q1 | 1.19 Million USD | -26.09% |
| 1998 Q3 | 1.14 Million USD | 20.0% |
| 1998 Q4 | 1.25 Million USD | 9.65% |
| 1998 FY | 4.53 Million USD | 14.68% |
| 1997 Q4 | 1.61 Million USD | 133.33% |
| 1997 FY | 3.95 Million USD | -11.63% |
| 1997 Q3 | 690 Thousand USD | -8.0% |
| 1997 Q2 | 750 Thousand USD | 44.23% |
| 1997 Q1 | 520 Thousand USD | -66.45% |
| 1996 Q2 | 1.08 Million USD | -2.7% |
| 1996 FY | 4.47 Million USD | 8.5% |
| 1996 Q4 | 1.55 Million USD | 112.33% |
| 1996 Q3 | 730 Thousand USD | -32.41% |
| 1996 Q1 | 1.11 Million USD | 5.71% |
| 1995 Q3 | 990 Thousand USD | -14.66% |
| 1995 Q4 | 1.05 Million USD | 6.06% |
| 1995 Q2 | 1.16 Million USD | 23.4% |
| 1995 Q1 | 940 Thousand USD | 95.83% |
| 1995 FY | 4.12 Million USD | 292.38% |
| 1994 Q1 | 230 Thousand USD | 0.0% |
| 1994 Q3 | 160 Thousand USD | -5.88% |
| 1994 Q4 | 480 Thousand USD | 200.0% |
| 1994 Q2 | 170 Thousand USD | -26.09% |
| 1994 FY | 1.05 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.86 Million USD | 100.0% |
| Ansell Limited | 495.5 Million USD | 100.0% |
| Ansell Limited | 495.5 Million USD | 100.0% |
| BG Medicine, Inc. | - USD | NaN% |
| Biotage AB (publ) | 82.8 Million USD | 100.0% |
| BioLife Sciences Inc. | - USD | NaN% |
| CB Scientific, Inc. | 1.73 Million USD | 100.0% |
| Psykey, Inc. | 1.21 Million USD | 100.0% |
| ConvaTec Group Plc | 910.31 Million USD | 100.0% |
| ConvaTec Group Plc | 872.5 Million USD | 100.0% |
| Encision Inc. | 3.77 Million USD | 100.0% |
| Golden Valley Development, Inc | 141.81 Thousand USD | 100.0% |
| Hear AtLast Holdings, Inc. | 109.93 Thousand USD | 100.0% |
| Innovative MedTech Inc. | 6.09 Million USD | 100.0% |
| LifePoint, Inc. | 7.42 Million USD | 100.0% |
| Medite Cancer Diagnostics, Inc. | 6.34 Million USD | 100.0% |
| Paradigm Medical Industries, Inc. | 855 Thousand USD | 100.0% |
| Remedent, Inc. | 726.13 Thousand USD | 100.0% |
| Reflect Scientific, Inc. | 1.06 Million USD | 100.0% |
| SmileDirectClub, Inc. | 517 Million USD | 100.0% |
| Sector 10, Inc. | 39.84 Thousand USD | 100.0% |
| Shandong Weigao Group Medical Polymer Company Limited | 6.64 Billion USD | 100.0% |
| SheerVision, Inc. | 2.33 Million USD | 100.0% |
| United Health Products, Inc. | 2.42 Million USD | 100.0% |
| Vasamed, Inc. | 4.67 Million USD | 100.0% |
| Wearable Health Solutions, Inc. | 2.56 Million USD | 100.0% |
| Yubo International Biotech Limited | 1.25 Million USD | 100.0% |